Analysts Offer Insights on Technology Companies: PaySign (PAYS), BlackBerry (BB) and Microsoft (MSFT)
The article highlights recent analyst ratings for three technology companies: PaySign (PAYS), BlackBerry (BB), and Microsoft (MSFT). Analysts from Barrington, CIBC, and Bank of America Securities maintained Buy ratings for these respective companies, with specific price targets and reported upsides. The sentiment across the board for these companies in the technology sector is largely bullish.
Analysts Offer Insights on Technology Companies: PaySign (PAYS), BlackBerry (BB) and Microsoft (MSFT)
Three analysts recently provided bullish sentiments on technology companies PaySign (PAYS), BlackBerry (BB), and Microsoft (MSFT). Gary Prestopino of Barrington maintained a Buy rating on PaySign with an $8.50 price target, while Todd Coupland from CIBC maintained a Buy rating on BlackBerry with a $6.00 price target. Bank of America Securities analyst Tal Liani also maintained a Buy rating on Microsoft, highlighting a consensus Strong Buy rating with an average target of $586.30.
Paysign (NASDAQ:PAYS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Paysign (NASDAQ:PAYS) from a "hold" to a "buy" rating, contributing to an overall "Moderate Buy" consensus among analysts with a price target of $9.42. This upgrade follows Paysign reporting Q4 earnings of $0.02 EPS, slightly missing estimates, but exceeding revenue expectations with $22.76 million. Institutional investors, including Punch & Associates, have significantly increased their stakes in the company, which specializes in prepaid payment solutions.
Paysign (PAYS) Is Up 67.6% After Strong 2026 Margin Guidance And Revenue Outlook - Has The Bull Case Changed?
Paysign (PAYS) recently announced strong 2026 guidance, including projected revenue of US$106.5–110.5 million and operating margins of 20–22%, which has positively impacted its stock price. The new outlook, especially the expected margin expansion from patient affordability programs, is reshaping the investment narrative. However, the company still faces concentration risk in plasma and pharma reimbursement sectors.
Paysign (PAYS) Is Up 67.6% After Strong 2026 Margin Guidance And Revenue Outlook - Has The Bull Case Changed?
Paysign (PAYS) has seen a significant stock increase following robust 2026 revenue and margin guidance, including projected Q1 revenue of US$27.0–27.5 million and full-year revenue of US$106.5–110.5 million, with improved operating and net margins. This guidance is driven by higher-margin patient affordability programs and a balanced plasma/pharma mix. Despite the positive outlook, the article notes the remaining concentration risk in its core markets as a key vulnerability.
Paysign (PAYS) Is Up 67.6% After Strong 2026 Margin Guidance And Revenue Outlook - Has The Bull Case Changed?
Paysign Inc. (PAYS) reported strong fourth-quarter 2025 revenue and provided optimistic 2026 guidance, including increased revenue projections and expanded operating and net margins, largely driven by higher-margin patient affordability programs. This positive outlook has led to a significant 67.6% stock increase. However, the company still faces concentration risks due to its heavy reliance on plasma and pharma payment solutions, which some analysts view with caution.
Paysign Inc. Earnings Call Highlights Rapid Profit Surge
Paysign Inc.'s Q4 earnings call revealed significant growth, with total revenue for fiscal 2025 reaching $82.0 million, a 40.5% increase year-over-year. Net income nearly doubled to $7.6 million, and adjusted EBITDA climbed 107% to $19.9 million, driven largely by its patient affordability platform, which saw revenue soar by 167.8%. Despite challenges in the plasma segment and regulatory uncertainties, the company forecasts strong growth and improved operating margins for 2026.
DA Davidson Reiterates Buy Rating for Paysign (NASDAQ:PAYS)
DA Davidson has reiterated a "Buy" rating for Paysign (NASDAQ:PAYS) with a $9.00 price target, suggesting a 70% upside. Other analysts also show a "Moderate Buy" consensus with an average target of $9.42. Paysign recently reported mixed Q1 earnings, missing EPS estimates but exceeding revenue expectations, and institutional ownership remains significant with firms like Goldman Sachs increasing their stakes.
PaySign, Inc. (NASDAQ:PAYS) Q4 2025 Earnings Call Transcript
PaySign, Inc. (NASDAQ:PAYS) held its Q4 and full-year 2025 earnings call, reporting strong growth with full-year revenue up 40.5% to $82 million and net income increasing 98% to $7.6 million. The company's patient affordability business was a primary growth driver, with annual revenue growing 168% year-over-year, alongside continued stability in its plasma donor compensation business. PaySign provided a positive outlook for 2026, expecting revenue growth of 30% to 35% and significant margin expansion, driven by its differentiated dynamic business rules technology in the patient affordability segment and anticipated advancements in its plasma division.
Executive pay and 2026 board, auditor votes at Paysign (NASDAQ: PAYS)
Paysign (NASDAQ: PAYS) will hold its 2026 annual shareholder meeting on May 8, 2026, where shareholders will vote on the election of seven directors and the ratification of Baker Tilly US, LLP as the auditor for 2026. The company's executive compensation is heavily equity-based, with the CEO receiving $2.75 million in 2025, including significant restricted stock grants tied to performance targets. Insiders and directors collectively control approximately 21.6% of the voting power, and the board is largely independent.
Copay aid became Paysign’s growth engine, lifting pharma revenue 168%
Paysign, Inc. reported strong financial results for Q4 and full-year 2025, with total annual revenue jumping 40.5% to $82 million, largely driven by its patient affordability offerings. Pharma revenue surged by 167.8% due to increased programs and claims processing, while plasma revenue also saw a 4.0% increase. The company delivered record top- and bottom-line figures, with Adjusted EBITDA more than doubling, and provided an optimistic outlook for 2026 with projected revenue growth of 30.0% to 35.0%.
Paysign Q4 Earnings Call Highlights
Paysign (NASDAQ: PAYS) reported robust Q4 and full-year 2025 results, with revenue up 40.5% to $82.0 million and net income doubling to $7.6 million, largely driven by its rapidly expanding patient affordability platform. The company ended 2025 with $21.1 million in cash and no bank debt, providing a strong financial position for future growth. Paysign provided an optimistic 2026 outlook, projecting revenue between $106.5 million and $110.5 million, highlighting continued growth in patient affordability and a stable plasma donor compensation business.
Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion
Paysign, Inc. (NASDAQ: PAYS) announced strong financial results for the fourth quarter and full-year 2025, driven significantly by its patient affordability offerings. The company reported a 40.5% increase in total revenues to $82.0 million for the full year, with patient affordability revenue surging by 167.8%. Paysign also provided an optimistic outlook for 2026, projecting continued revenue growth and margin expansion, with anticipated net income nearly doubling.
Paysign (NASDAQ:PAYS) Given New $11.00 Price Target at Lake Street Capital
Lake Street Capital increased its price target for Paysign (NASDAQ:PAYS) from $10.00 to $11.00, maintaining a "buy" rating, indicating a potential upside of 117.35%. This news follows Paysign's strong Q4 financial results, which reported revenue of $22.76 million, exceeding estimates, and projected 30-35% revenue growth for 2026. Despite a slight EPS miss, the stock surged 34.2% to $5.06, driven by positive sentiment around its future growth targets and increased institutional investment.
DA Davidson reiterates Paysign stock Buy rating on strong Q4 growth
DA Davidson reaffirmed its Buy rating and $9.00 price target for Paysign Inc. (NASDAQ:PAYS) after the company reported strong fourth-quarter results, exceeding analyst forecasts for revenue and adjusted EBITDA. Paysign also provided optimistic 2026 guidance, projecting significant year-over-year growth in both revenue and adjusted EBITDA, further supporting DA Davidson's positive outlook. The company's recent Q4 2025 earnings also met EPS expectations and surpassed revenue forecasts, indicating robust financial health.
Paysign Projects Unprecedented Revenue Growth Amid Record 2025 Earnings
Paysign Inc.'s stock surged over 30% following a strategic partnership announcement and record-breaking 2025 earnings, with revenue up 40.5% and net income nearly doubling. The company projects continued strong growth for 2026, with an acquisition further enhancing its market position and potential to double previous year's numbers. This performance has sparked significant investor optimism and market buzz.
[10-K] Paysign, Inc. Files Annual Report
Paysign, Inc. (PAYS) has filed its annual report (Form 10-K) for the fiscal year ended December 31, 2025, detailing its financial performance, outlining business operations, and discussing risks. The report indicates significant revenue growth, particularly in the pharma industry segment, and highlights the company's vertically integrated prepaid card products, processing services, and life science technology solutions. It also covers legal proceedings and cybersecurity risk management strategies.
Paysign, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results; Patient Affordability Drives 40% Revenue Growth and Significant Margin Expansion
Paysign, Inc. announced strong financial results for Q4 and full-year 2025, with total revenues increasing by 40.5% to $82.0 million for the year, primarily driven by a 167.8% growth in patient affordability programs. The company reported a significant increase in net income and Adjusted EBITDA, attributing growth to increased pharma and plasma business, despite a decline in average plasma donations per center. Paysign also provided an optimistic outlook for 2026, projecting continued revenue growth and margin expansion, underpinned by ongoing investments in technology and people.
Paysign Inc.’s Earnings Call: FDA Timeline Shifts and Revenue Stream Contradictions Clash
Paysign Inc. reported strong financial growth for 2025, with revenue up 40.5% to $82 million, driven by patient affordability and plasma businesses. The company provided optimistic guidance for 2026, including projected revenue growth of 30%-35% and significant margin expansion, attributing success to operational leverage and strategic positioning. However, the article highlights several inconsistencies in management's statements regarding revenue per program, the FDA review timeline for their BECS system, growth outlook for the pharma business, and drivers of plasma revenue growth, which could cause investor confusion.
Paysign Inc.’s Earnings Call: FDA Timeline Shifts and Revenue Stream Contradictions Clash
Paysign Inc. reported strong financial growth for the full year 2025, with revenue increasing by 40.5% to $82 million, driven by its patient affordability and plasma donor compensation businesses. The company provided a positive outlook for 2026, expecting 30%-35% revenue growth and significant improvements in operating leverage and profitability. However, the article highlights several contradictions identified during the earnings call regarding revenue per program, the FDA timeline for a new donor management system, growth outlook for the pharma business, and plasma revenue growth drivers.
Paysign Reports 40.5% Revenue Growth in 2025 Financial Results
Paysign (PAYS) reported significant financial growth in 2025, with total revenues reaching $82 million, a 40.5% increase year-over-year. This growth was fueled by the expansion of plasma centers and patient affordability programs, leading to substantial increases in both plasma and pharma revenues. The company also achieved a 97.9% rise in net income to $7.55 million and maintains a strong financial position with $21.07 million in unrestricted cash and zero debt.
Paysign Reports FY2025 Revenue $82.0M, Net Income $7.55M and Adjusted EBITDA $19.94M
Paysign reported strong financial results for full-year 2025, with total revenues reaching $82.02 million, a 40.5% increase year-over-year. The company's net income was $7.55 million, and Adjusted EBITDA stood at $19.94 million. Growth was primarily driven by significant expansion in its patient affordability business and an increased footprint in the plasma industry.
Paysign (NASDAQ:PAYS) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS
Paysign (NASDAQ:PAYS) announced its quarterly earnings, reporting $0.02 EPS, which was $0.01 below analyst expectations, though revenue of $22.76 million surpassed estimates. Following the announcement, Paysign's stock surged by 12.9% to $3.77 on significantly higher trading volume. Analysts currently hold a "Moderate Buy" consensus rating for PAYS with a price target of $8.56.
PAYS Q4'25 Earnings: EPS estimate is 0.02 USD
Paysign, Inc. (PAYS) is scheduled to announce its Q4'25 earnings on March 24th, with an estimated revenue of $21.54 million and earnings per share (EPS) of $0.02. The article provides a historical overview of PAYS's revenue and EPS figures, including reported and estimated values, as well as surprise percentages for previous quarters.
Wall Street Zen Downgrades Paysign to Hold
Wall Street Zen has downgraded Paysign, Inc. (NASDAQ: PAYS) from a "buy" to a "hold" rating due to concerns about the financial technology company's recent financial performance and growth outlook. This downgrade could impact investor sentiment and trading activity for Paysign, a small-cap fintech specializing in prepaid payment solutions. Investors are now watching if other firms will follow suit, highlighting the volatility in the fintech sector.
Paysign (NASDAQ:PAYS) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen has downgraded Paysign (NASDAQ:PAYS) from a "buy" to a "hold" rating, while Weiss Ratings reissued its "hold (c)" rating. Despite the downgrade, analysts maintain a "Moderate Buy" consensus with an average target price of $8.56. Large institutional investors, including Palisades Investment Partners LLC, New York State Common Retirement Fund, and Royce & Associates LP, have significantly increased their stakes in Paysign, indicating continued institutional interest despite the lowered rating.
Paysign Inc expected to post earnings of 2 cents a share - Earnings Preview
Paysign Inc (PAYS) is anticipated to report earnings of 2 cents per share. This information comes from a Reuters earnings preview. The article is a brief financial news update.
PAYS Q4'25 Earnings: revenue estimate is 21.54M USD
Paysign, Inc. (PAYS) is scheduled to announce its Q4'25 earnings on March 24, with revenue estimated at $21.54 million and EPS at $0.02. The article provides a table of past reported and estimated revenues and EPS, highlighting previous surprises. It also includes a disclaimer about reference data provided by FactSet.
Paysign (PAYS) Projected to Post Quarterly Earnings on Tuesday
Paysign (PAYS) is anticipated to report its Q4 2025 earnings after the market closes on Tuesday, March 24, 2026. Analysts project earnings of $0.03 per share on revenues of $21.54 million. The company currently holds a "Moderate Buy" rating from Wall Street analysts, with an average price target of $8.56.
Paysign (NASDAQ:PAYS) Upgraded to "Buy" at Wall Street Zen
Wall Street Zen has upgraded Paysign (NASDAQ:PAYS) from a "hold" to a "buy" rating. The company currently has a "Moderate Buy" consensus rating from analysts, with an average price target of $8.56. Paysign's shares opened at $3.44, and institutional investors have recently adjusted their holdings in the company.
Paysign (PAYS) CFO exercises 60,000 shares, withholds stock for tax
Paysign, Inc.'s CFO, Jeffery Bradford Baker, exercised a derivative award for 60,000 shares on February 28, 2026, receiving common stock at $0.00 per share. Concurrently, 26,055 common shares were withheld at $3.55 per share to cover tax obligations related to the vesting of restricted stock units. Following these transactions, Baker directly owned 386,218 shares of Paysign common stock, indicating a routine conversion of vested awards into direct ownership.
Paysign (NASDAQ:PAYS) Downgraded to Hold Rating by Wall Street Zen
Wall Street Zen has downgraded Paysign (NASDAQ:PAYS) from a "buy" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $8.56. The stock opened down about 3.3% at $3.55, with a market cap of $195.4 million. Insider Robert Strobo recently sold 20,000 shares, reducing his stake by 5.76%.
PAYS Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Paysign Inc (PAYS), including its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2024. It highlights the company's strong revenue growth (23.5% YoY), robust cash flow generation, and low debt, but also notes its elevated financial distress risk according to the Altman Z-Score and moderate profitability metrics. The report assesses profitability, growth, leverage, liquidity, cash flow, and shareholder returns, alongside a comprehensive FAQ section addressing common financial queries.
PAYS Earnings - {quarter} AI Prediction - Intellectia AI™
Intellectia AI provides an earnings prediction for Paysign Inc (PAYS) ahead of its scheduled earnings release on March 26, 2026, after hours. The article highlights PAYS's recent strong financial performance, including significant revenue and net income increases, driven by its pharma revenue and strategic acquisitions, despite challenges in the plasma segment. Intellectia's AI algorithms offer forecasts on whether Paysign will beat or miss analyst expectations for revenue and EPS, enabling investors to strategize their trades.
PAYS Technical Analysis & ETF Price Forecast
This article provides a technical analysis and ETF price forecast for Paysign Inc (PAYS). While the overall technical sentiment is Neutral, various moving averages suggest a "Buy" signal for PAYS, despite a static share price of $3.55. The analysis delves into momentum indicators, support and resistance levels, and different moving average periods.
Paysign to Host Fourth Quarter and Full Year 2025 Earnings Call
Paysign, Inc. (NASDAQ: PAYS) announced it will host an earnings call for its fourth quarter and full year 2025 results on Tuesday, March 24, 2026, at 5:00 p.m. Eastern time. The company, a provider of patient affordability and donor compensation solutions in life sciences, has provided dial-in and webcast details for participants, with a replay available until June 24, 2026. Financial professionals wishing to ask questions must register by March 20, 2026.
Paysign to Host Fourth Quarter and Full Year 2025 Earnings Call
Paysign, Inc. (NASDAQ: PAYS) announced it will host its fourth quarter and full year 2025 earnings call on Tuesday, March 24, 2026, at 5:00 p.m. Eastern time. The call details, including dial-in numbers and webcast link, were provided, and a replay will be available until June 24, 2026. Financial professionals wishing to ask questions during the call must register by emailing [email protected] by March 20, 2026.
Paysign, Inc. (NASDAQ:PAYS) Given Consensus Rating of "Moderate Buy" by Analysts
Paysign, Inc. (NASDAQ:PAYS) has received a consensus "Moderate Buy" rating from five analysts, with an average 1-year target price of $8.56. The company's shares opened at $3.28, trading below their 12-month high, and have a market capitalization of $180.53 million. Insider Robert Strobo recently sold 20,000 shares, while institutional investors like Goldman Sachs have increased their stakes.
Wall Street Zen Upgrades Paysign (NASDAQ:PAYS) to "Buy"
Wall Street Zen has upgraded Paysign (NASDAQ:PAYS) from a "hold" to a "buy" rating, leading to a consensus "Moderate Buy" rating among analysts with an average price target of $8.56. This upgrade follows Paysign's reported quarterly EPS of $0.04, which met estimates, and revenue of $21.6 million, exceeding analysts' expectations. The article also notes recent insider selling activity and institutional investment in the company.
New York State Common Retirement Fund Raises Stake in Paysign, Inc. $PAYS
The New York State Common Retirement Fund significantly increased its stake in Paysign, Inc. (NASDAQ:PAYS) by 2,943.3% in the third quarter of 2025, now holding 385,732 shares valued at approximately $2.43 million. Other institutional investors also adjusted their positions, and analysts maintain a "Moderate Buy" rating for Paysign with a consensus target price of $8.56. Paysign reported strong Q3 earnings, meeting EPS expectations and beating revenue forecasts, and provided positive FY2025 EPS guidance.
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. (NASDAQ:PAYS) has experienced a 27% share price drop in the last month, though its stock still gained 37% over the past year. Despite a P/E ratio higher than the market average, analysts anticipate Paysign's EPS to climb by 19% in the coming year, outperforming the market's 16% prediction. This expected strong future growth for Paysign contributes to its elevated P/E ratio, suggesting investor confidence in its potential.
The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. (NASDAQ:PAYS) has experienced a 27% share price drop in the last month, though it's still up 37% over the past year. Despite its current high P/E ratio compared to the market, analysts forecast stronger earnings growth for Paysign than the general market, which may justify its higher valuation to investors. The article suggests that investors are focusing on the company's anticipated future growth rather than its recent dips in performance.
Paysign, Inc. (PAYS) Presents at Oppenheimer 11th Annual Emerging Growth Conference - Slideshow
Paysign, Inc. (PAYS) delivered a slideshow presentation at the Oppenheimer 11th Annual Emerging Growth Conference on February 2, 2026. The article highlights that the slide deck from this event has been published. The information is provided by SA Transcripts, which focuses on providing transcripts and related projects.
Paysign, Inc. (NASDAQ:PAYS) Given Average Rating of "Moderate Buy" by Analysts
Paysign, Inc. (NASDAQ:PAYS) has received an average "Moderate Buy" rating from five analysts, with a 1-year average target price of $8.56. Insider Robert Strobo recently sold 20,000 shares, reducing his holding by 5.76%. The company's latest quarterly earnings saw EPS of $0.04 and revenue of $21.6M, exceeding revenue estimates, and FY2025 EPS guidance is set at $0.120-$0.130.
Palisades Investment Partners LLC Buys Shares of 897,634 Paysign, Inc. $PAYS
Palisades Investment Partners LLC acquired a new position of 897,634 shares of Paysign, Inc. (NASDAQ:PAYS) during the third quarter, valued at approximately $5.65 million, making it their 19th-largest holding. Paysign has a "Moderate Buy" consensus rating from analysts with an average target price of $8.56, and recently reported Q3 EPS of $0.04 and revenue of $21.6M. The company has a current market cap of about $248 million and has issued FY2025 EPS guidance of $0.120–0.130.
Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
Paysign, Inc. (NASDAQ: PAYS), a fintech and healthcare company, announced its participation in the Oppenheimer 11th Annual Emerging Growth Conference on February 3-4, 2026. Paysign's CFO, Jeff Baker, will host one-on-one meetings to showcase the company's patient affordability programs, donor compensation solutions, and integrated payment processing for life sciences. The conference will feature emerging companies in technology, industrial growth, and consumer sectors in a virtual format.
Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the Oppenheimer 11th Annual Emerging Growth Conference, which will be held virtually on February 3-4, 2026. Paysign's CFO, Jeff Baker, will host one-on-one meetings on February 3rd. The conference focuses on emerging technology, industrial growth, and consumer sectors, providing an opportunity for investors to engage with Paysign, a company specializing in fintech and healthcare payment solutions.
Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the Oppenheimer 11th Annual Emerging Growth Conference, which will be held virtually on February 3-4, 2026. The company's Chief Financial Officer, Jeff Baker, will host one-on-one meetings with investors on February 3. Paysign specializes in fintech and healthcare, providing payment processing and program management for plasma, pharmaceutical, and life sciences industries.
Paysign to Present at Oppenheimer 11th Annual Emerging Growth Conference in February 2026
Paysign (PAYS) will present at the Oppenheimer 11th Annual Emerging Growth Conference virtually on February 3-4, 2026, with CFO Jeff Baker hosting one-on-one meetings. The company specializes in patient affordability and donor compensation solutions for the life sciences sector, leveraging proprietary payment processing technology. Analyst ratings show a positive outlook for PAYS, with an average 1-year price target of $9.00 among four analysts.
Paysign, Inc. to Present at the Oppenheimer 11th Annual Emerging Growth Conference
Paysign, Inc. (NASDAQ: PAYS) announced its participation in the Oppenheimer 11th Annual Emerging Growth Conference, which will take place virtually on February 3-4, 2026. Paysign's CFO, Jeff Baker, will host one-on-one meetings with investors interested in the company's fintech and healthcare solutions. The conference focuses on emerging companies in technology, industrial growth, and consumer sectors.
